Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
VEOS Group is a Belgian private company that produces functional animal- and egg-derived protein ingredients for food, para-pharma, and specialized animal nutrition markets including feed, pet food, and aquafeed. Founded in 1974, the group describes itself as a specialized global leader in the animal protein market, with headquarters in Belgium and a global production and sales footprint. Its portfolio includes blood- and egg-based protein ingredients sold through group brands and operating entities such as VEOS, ACTIPRO, Vepro, and Naplasol. The company emphasizes circular processing of animal by-products, sustainability, and manufacturing scale rather than human therapeutic drug development. Recent strategic moves include acquiring OvaInnovations’ operations in the United States and, through group member Naplasol, acquiring Swedish mycoprotein company Mycorena.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on VEOS Group.